吸入β_2激动剂和小剂量皮质类固醇的联合疗法通常能控制大多数有轻度症状的哮喘。然而,少数重症慢性哮喘患者持续口服皮质类固醇。鉴于对难治性哮喘患者长期口服皮质类固醇的忧虑,作者用安慰剂对照、双盲交叉研究对12例重症慢性哮喘患者比较肌注360mg/次去炎松3天和口服强的松15mg/d3个月的疗效。治疗开始均有明显的皮质类固醇副作用,9例有柯兴综合征面容,3例高血压,2例糖尿病(需饮食控制),1倒过度肥胖。肌注去炎松时肺功能改善,峰值流量达平均预计值的91.5％、而口服强的松患者为75％。用去炎松治疗期间无患者需急诊和住 Combination therapy with inhaled beta-2 agonists and low-dose corticosteroids usually controls most of the mild symptoms of asthma. However, a small number of patients with severe chronic asthma continued oral corticosteroids. In view of the long-term oral corticosteroids in patients with refractory asthma, the authors placebo-controlled, double-blind crossover study of 12 patients with severe chronic asthma compared intramuscular 360mg / times triamcinolone 3 days and oral prednisone 15mg / d3 The efficacy of months. There were obvious corticosteroid side effects at the beginning of treatment, 9 cases had Cushing’s syndrome, 3 cases of hypertension, 2 cases of diabetes mellitus (diet control) and 1 over-obesity. Pulmonary function was improved during intramuscular injection of mast cells, with an average peak-to-peak flow of 91.5%, compared with 75% of patients taking oral prednisone. No patients need emergency treatment and stay during treatment with triamcinolone